Breztri

Drug Overview

In the clinical field of Pulmonology, the management of Chronic Obstructive Pulmonary Disease (COPD) has evolved toward “Triple Therapy” to address the multi-faceted nature of the disease. Breztri (known in some markets as Breztri Aerosphere) is a primary example of this advanced approach. Classified as an ICS / LAMA / LABA Combination, it integrates three distinct medications into a single inhaler to provide comprehensive maintenance for patients who remain symptomatic despite dual-therapy regimens.

For individuals living with chronic respiratory failure or obstructive airway diseases, Breztri offers a streamlined treatment path. By combining an anti-inflammatory agent with two different types of long-acting airway relaxants, this medication targets the lungs from three different angles, aiming to keep patients out of the hospital and breathing more easily.

• Generic Name: Budesonide, Glycopyrrolate, and Formoterol Fumarate
• US Brand Names: Breztri Aerosphere
• Route of Administration: Metered-Dose Inhaler (MDI) utilizing Aerosphere delivery technology.
• FDA Approval Status: Fully FDA-approved for the long-term maintenance treatment of COPD.

What Is It and How Does It Work? (Mechanism of Action)

Breztri operates through three distinct molecular pathways to stabilize the respiratory environment. This Targeted Therapy addresses the “squeeze” of the muscles, the “clog” of the mucus, and the “swell” of the airway lining simultaneously.

1. Budesonide (ICS): This is an Inhaled Corticosteroid (ICS). It diffuses across cell membranes and binds to glucocorticoid receptors in the cytoplasm. The receptor-drug complex moves into the cell nucleus, where it suppresses the genes responsible for producing pro-inflammatory cytokines. This reduces the overall swelling and sensitivity of the airway walls.
2. Glycopyrrolate (LAMA): As a Long-Acting Muscarinic Antagonist (LAMA), it works through muscarinic receptor antagonism. It blocks the M3 muscarinic receptors on the smooth muscles of the lungs. Normally, a chemical called acetylcholine binds to these receptors to make the muscles tighten; by blocking this signal, glycopyrrolate keeps the muscles relaxed and reduces excess mucus production.
3. Formoterol Fumarate (LABA): This is a Long-Acting Beta-2 Agonist (LABA). It works through beta-2 adrenoceptor agonism. It binds to receptors on the smooth muscle cells, stimulating an enzyme called adenyl cyclase. This increases the levels of cyclic AMP, which signals the muscles to relax.

By combining these three actions, Breztri provides a synergistic effect where the two types of Bronchodilator relax the airways while the steroid reduces the underlying inflammation that causes “flare-ups.”

FDA-Approved Clinical Indications

Breztri is utilized strictly for the maintenance and prevention of COPD symptoms.

• Primary Indication: Maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema.
• Other Approved & Off-Label Uses: While the individual components are used in asthma, Breztri as a triple-combination MDI is specifically FDA-approved for COPD. It is not indicated for the relief of acute bronchospasm.

Primary Pulmonology Indications:

• Improvement of Ventilation: By providing dual-action bronchodilation, it maximizes the diameter of the bronchial tubes, significantly reducing the “work of breathing.”
• Reduction in Exacerbations: It is specifically designed to reduce the frequency of moderate-to-severe flare-ups that lead to emergency room visits.
• Slowing Decline of Lung Function: Through consistent inflammation control, it helps preserve remaining lung capacity and improves the patient’s daily physical stamina.

Dosage and Administration Protocols

Breztri is administered twice daily. Because it contains a steroid, specific post-inhalation hygiene is required to prevent localized infections.

Administration Instructions:

• Technique: Shake the inhaler well before each use. Breathe out fully away from the device. Place the mouthpiece between the lips and press the canister while breathing in slowly and deeply. Hold the breath for 10 seconds.
• Post-Inhalation Care: Patients MUST rinse their mouth with water and spit it out after each dose. This is essential to prevent oropharyngeal candidiasis (thrush).
• Priming: If the inhaler is new or hasn’t been used for more than 7 days, it must be primed by spraying into the air 4 times.
• Warning: Breztri is a maintenance medication. It is not a short-acting (SABA/SAMA) therapy and will not stop an acute attack of breathlessness.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical study data from 2020–2026 has established Breztri as a highly efficacious Targeted Therapy. In the landmark ETHOS trial, Breztri was compared against dual-therapy inhalers in over 8,000 patients with moderate-to-very-severe COPD.

Key numerical data from recent research includes:

• Exacerbation Rates: Breztri demonstrated a 24% to 52% reduction in the rate of moderate or severe COPD exacerbations compared to dual therapies (LAMA/LABA or ICS/LABA).
• FEV1 Improvements: Patients showed a mean improvement in trough Forced Exhalatory Volume in 1 second (FEV1) of approximately 147 mL to 175 mL over baseline.
• Quality of Life: Significant improvements were noted in the St. George’s Respiratory Questionnaire (SGRQ) scores, indicating better daily function and less fatigue.
• 6-Minute Walk Distance (6MWD): Treated patients showed increased exercise tolerance, directly correlating to better oxygen saturation during physical activity.

Safety Profile and Side Effects

Black Box Warning: There is no “Black Box Warning” for Breztri. (Note: The previous warning regarding LABA and asthma death was removed for ICS-containing combinations).

Common Side Effects (>10%):

• Upper respiratory tract infection
• Headache
• Back pain
• Oral candidiasis (thrush)

Serious Adverse Events:

• Pneumonia: Inhaled steroids in COPD patients are associated with an increased risk of pneumonia.
• Cardiovascular Stimulation: The LABA component can cause increased heart rate, blood pressure, and arrhythmias.
• Narrow-Angle Glaucoma: The LAMA component can worsen eye pressure if sprayed into the eyes.
• Urinary Retention: Caution is required for patients with an enlarged prostate.
• Paradoxical Bronchospasm: A rare but life-threatening event where the airway tightens immediately after use.

Management Strategies:

• Thrush Prevention: Strict “Rinse and Spit” protocol.
• Rescue Inhaler: Always have a SABA (like albuterol) available for sudden symptoms.
• Heart Rate Monitoring: Patients with cardiac history should have regular check-ups.

Research Areas

Direct Clinical Connections: Current research (2024–2026) is investigating Breztri’s effect on airway remodeling. By using high-resolution CT scans, scientists are measuring if this triple combination can physically reduce the thickening of the airway walls over time.

Generalization: Advancements in Novel Delivery Systems include “Smart” Aerosphere inhalers that use Bluetooth to track adherence. This ensures that the Targeted Therapy is delivered at the correct time, preventing end-stage lung disease through better compliance.

Severe Disease & Precision Medicine: Research is focusing on “Biologic” phenotyping—specifically using blood eosinophil counts to predict which COPD patients will benefit most from the ICS component in Breztri versus a LAMA/LABA dual therapy.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Spirometry (PFTs) to establishing baseline FEV1, Chest X-ray or CT scan, and Pulse Oximetry (SpO2).
• Organ Function: Baseline heart rate and blood pressure monitoring.
• Specialized Testing: Sputum eosinophil counts or blood eosinophil levels to phenotypically categorize the COPD.
• Screening: Review of inhalation technique and a thorough tobacco use history.

Monitoring and Precautions

• Vigilance: Monitor for “Step-up” or “Step-down” needs based on the COPD Assessment Test (CAT) or SGRQ scores.
• Lifestyle: Smoking cessation is an absolute requirement. Patients are encouraged to perform pulmonary rehabilitation exercises and keep up to date with vaccinations (Flu/Pneumonia/COVID-19).

“Do’s and Don’ts”

• DO use Breztri every single day, twice a day, even if you feel well.
• DO rinse your mouth and spit after every dose.
• DO keep your inhaler clean by wiping the mouthpiece with a dry tissue.
• DON’T use Breztri to treat a sudden, acute attack of shortness of breath.
• DON’T swallow the water you use for rinsing.
• DON’T take more than the prescribed number of puffs.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Breztri should only be used as prescribed by a licensed healthcare professional. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.